Park National Corp OH Decreases Stock Holdings in AbbVie Inc. $ABBV

Park National Corp OH reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 110,555 shares of the company’s stock after selling 7,072 shares during the quarter. Park National Corp OH’s holdings in AbbVie were worth $25,598,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ABBV. Hobart Private Capital LLC lifted its position in AbbVie by 4.4% during the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock valued at $261,000 after purchasing an additional 48 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of AbbVie by 1.1% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company’s stock valued at $848,000 after acquiring an additional 51 shares during the last quarter. FF Advisors LLC lifted its holdings in shares of AbbVie by 3.6% in the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock valued at $286,000 after acquiring an additional 53 shares during the last quarter. Landaas & Co. WI ADV grew its position in AbbVie by 1.1% in the second quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock worth $920,000 after acquiring an additional 53 shares in the last quarter. Finally, Bernardo Wealth Planning LLC grew its position in AbbVie by 2.9% in the second quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company’s stock worth $354,000 after acquiring an additional 53 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of recent research reports. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their target price on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. BMO Capital Markets raised their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, September 12th. Evercore ISI lifted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Finally, Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $244.55.

AbbVie Price Performance

ABBV opened at $227.53 on Tuesday. The business has a fifty day moving average of $227.20 and a 200 day moving average of $210.24. The stock has a market cap of $402.14 billion, a P/E ratio of 172.37, a PEG ratio of 1.21 and a beta of 0.36. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period last year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is presently 496.97%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.